This biotech is forecasted to grow at an annual rate of 35.6% over the next five years.
MannKind Corporation (MNKD)
From Nate’s Notes
It has been an exciting first half of the year so far for my Top Pick for 2021, MannKind Corporation.
The stock has been climbing steadily this year 1) in anticipation of continued growth for the company’s lead product, Afrezza (an inhalable form of mealtime insulin for both Type 1 and Type 2 diabetics); and 2) the fact that one of the company’s partners, United Therapeutics (UTHR), has filed a New Drug Application (NDA) with the FDA for an improved version of treprostinil that utilizes MannKind’s Technosphere drug delivery platform.
In addition, another of the company’s licensees of the technology, a private company called Receptor Life Sciences, announced very exciting clinical data related to its efforts to develop pharmaceutical grade CBD products utilizing the Technosphere platform as well.
After raising over $200 million in a convertible debt offering earlier this year, the company is in the best financial shape it has been in for many years now, and though it is not the same screaming bargain at today’s prices that it was at $1 a little over a year ago, MNKD is still considered a very strong buy under $5 and a buy under $10.
Nate Pile, Nate’s Notes, NotWallStreet.com, 707-433-7903, June 30, 2021